What is myPath® Melanoma?
Myriad Genetic Laboratories has developed myPath® Melanoma, a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone. Reasons that definitive diagnosis may not be achievable by histopathology include indeterminate or ambiguous histopathologic features, diagnostic disagreement among physicians, or indications that additional workup or consultation are necessary.
The test measures the expression of 23 genes by qRT-PCR methodology and distinguishes melanoma from nevi with a sensitivity of 90-94% and a specificity of 91-96%. 7,29,30
90% - 94%
91% - 96%
In light of the public health preparedness efforts currently underway, Myriad’s top priorities are protecting the health and safety of employees, our customers, and their patients.
Click here to learn more about our measures to help keep you and your patients safe.
Test Submission Process
How the myPath Melanoma Test Works
Covered by Medicare
9 out of 10 patients pay $0
The estimated average out-of-pocket cost
after insurance and financial assistance